| Ytd | -10.88% | |
| 1y | 126.14% |
| Open | 31.00 | Prev Close | 30.70 | Low | 30.77 | High | 34.05 | Mkt Cap | 1.44B |
| Vol | 1.63M | Avg Vol | 772.06K | EPS | -5.03 | P/E | -6.43 | Forward P/E | -12.69 |
| Beta | -0.96 | Short Ratio | 13.37 | Inst. Own | 90.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 22.12 | 200-d Avg | 25.44 | 1yr Est | 42.13 |
ZBIO News
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (
Zenas BioPharma (ZBIO) is positioned as more than a rare-disease play, leveraging obexelimab's B-cel
CEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18,
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (
US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma”
- The INDIGO study met its primary and all key secondary endpoints with statistically significant re
- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass. , May 28, 2026
- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre,
WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (N
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB0
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA
Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”)
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares rose 7.6% during trading on Thursday a
Twist Bioscience (NASDAQ: TWST - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Repor
U.S. stocks down, NASDAQ drops 1.5% on Friday. Energy shares up, consumer discretionary down. Univer
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu
Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-mar
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma”
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma”
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) has received a consensus recommendation of "H
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
